SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

Views:
24527
Likes:
7

Views:
24527
Likes:
7
Share:

Now Playing
Part 1 | Session 4 of 6
SGLT2 Inhibitors in Cardiology Indications: The Data
John JV McMurray

Up Next
9m 38s

Part 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data
Katherine Tuttle
14m 38s

Part 1 | Session 6 Panel Discussion
Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle

9m 39s

Part 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm
Andrew JS Coats
8m 1s

Part 2 | Session 2 SGLT2 Inhibitors: Safety Considerations
Gerasimos Filippatos
7m 39s

Part 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice
Javed Butler
6m 58s

Part 2 | Session 4 Panel Discussion
Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker

3m 56s

Part 3 | Session 1 Totality of Evidence for the Cardiorenal Patient
Alice Cheng, Andrew JS Coats
50m 42s

Part 3 | Session 2 Discussion
Alice Cheng, Andrew JS Coats

1m 55s

Part 4 | Session 1 Welcome and Introduction
Shelley Zieroth, John Spertus
43m

Part 4 | Session 2 KCCQ Score Overview and Discussion
Shelley Zieroth, John Spertus

1m 11s

Part 5 | Session 1 Welcome and Introduction
Gerasimos Filippatos, Giuseppe Rosano
7m 5s

Part 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients
Gerasimos Filippatos
27m 15s

Part 5 | Session 3 Discussion
Giuseppe Rosano, Gerasimos Filippatos

1m 20s

Part 6 | Session 1 Welcome and Introduction
Stefan Anker, Mark Petrie
11m 2s

Part 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?
Subodh Verma
11m 24s

Part 6 | Session 3 Totality of Evidence in Heart Failure
Deepak L Bhatt
11m 20s

Part 6 | Session 4 Trial Results Coming Out Soon
Stefan Anker
10m 55s

Part 6 | Session 5 Heart Failure Guidelines
Marco Metra
14m 37s

Part 6 | Session 6 Panel Discussion
Stefan Anker, Mark Petrie, Deepak L Bhatt, Marco Metra

1m 1s

Part 7 | Session 1 Welcome and Introduction
Stefan Anker, Mark Petrie, Marco Metra
17m 18s

Part 7 | Session 2 Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Milton Packer
11m 29s

Part 7 | Session 3 Panel Discussion
Stefan Anker, Mark Petrie, Marco Metra

11m 8s

Part 8 | Session 1 Welcome and Introduction
Mark Petrie, Deepak L Bhatt
6m 43s

Part 8 | Session 2 Soloist Trial Overview
Deepak L Bhatt
36m 32s

Part 8 | Session 3 Discussion
Mark Petrie, Deepak L Bhatt

50m 20s

Part 9 Managing Patients with Comorbidities (T2D & CKD)
Paola Fioretto, Katherine Tuttle

25m 59s

Part 10 Interdisciplinary Collaboration and Care Transitions
Subodh Verma

53s

Part 1 | Session 1 Welcome and Introduction Stefan Anker, Shelley Zieroth

10m 23s

Part 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman

9m 18s

Part 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer

Average (ratings)

No ratings

Your rating

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
Apply findings from clinical trials into clinical practice
Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
Evaluate the safety and cardiorenal benefits of glucose-lowering agents
Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

Cardiologists
Nephrologists
Endocrinologists

More from this programme

Part 1

State of the Art 1

6 sessions
Welcome and Introduction	Watch now
SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started	Watch now
SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection	Watch now
SGLT2 Inhibitors in Cardiology Indications: The Data	Watch now
SGLT2 Inhibitors in Chronic Kidney Disease: The Data	Watch now
Panel Discussion	Watch now

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

4 sessions
Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm	Watch now
SGLT2 Inhibitors: Safety Considerations	Watch now
How to Use SGLT2 Inhibitors in Daily Practice	Watch now
Panel Discussion	Watch now

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

2 sessions
Totality of Evidence for the Cardiorenal Patient	Watch now
Discussion	Watch now

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

2 sessions
Welcome and Introduction	Watch now
KCCQ Score Overview and Discussion	Watch now

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

3 sessions
Welcome and Introduction	Watch now
SGLT2i in the Elderly and Vulnerable Patients	Watch now
Discussion	Watch now

Part 6

State of the Art 2

6 sessions
Welcome and Introduction	Watch now
How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?	Watch now
Totality of Evidence in Heart Failure	Watch now
Trial Results Coming Out Soon	Watch now
Heart Failure Guidelines	Watch now
Panel Discussion	Watch now

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

3 sessions
Welcome and Introduction	Watch now
Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care	Watch now
Panel Discussion	Watch now

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

3 sessions
Welcome and Introduction	Watch now
Soloist Trial Overview	Watch now
Discussion	Watch now

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

1 session
Managing Patients with Comorbidities (T2D & CKD)	Watch now

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

1 session
Interdisciplinary Collaboration and Care Transitions	Watch now

Faculty Biographies

John JV McMurray

Professor of Cardiology

Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.

Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.

View full profile